RECAB-ASA; Treatment of Recurrent Abortion With Aspirin
Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to examine whether treatment with 75 mg aspirin daily compared with
placebo could reduce the risk for a new miscarriage. The treatment starts when the pregnancy
is detected on transvaginal ultrasound (around gestational week 6+) and continues to week
35/36. The study is a single center, randomized, placebo-controlled, double blind and
stratified for age. 400 participants with the diagnosis idiopathic recurrent abortion are
enrolled, 200 in each arm aspirin / placebo.